These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22721569)

  • 1. Flecainide, a therapeutic option in a patient with long QT syndrome type 3 caused by the heterozygous V411M mutation in the SCN5A gene.
    Carrasco JI; Izquierdo I; Medina P; Arnau MÁ; Salvador A; Zorio E
    Rev Esp Cardiol (Engl Ed); 2012 Nov; 65(11):1058-9. PubMed ID: 22721569
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?
    Benhorin J; Taub R; Goldmit M; Kerem B; Kass RS; Windman I; Medina A
    Circulation; 2000 Apr; 101(14):1698-706. PubMed ID: 10758053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific Therapy Based on the Genotype in a Malignant Form of Long QT3, Carrying the V411M Mutation.
    Blich M; Khoury A; Suleiman M; Lorber A; Gepstein L; Boulous M
    Int Heart J; 2019 Jul; 60(4):979-982. PubMed ID: 31257342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
    Windle JR; Geletka RC; Moss AJ; Zareba W; Atkins DL
    Ann Noninvasive Electrocardiol; 2001 Apr; 6(2):153-8. PubMed ID: 11333173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term flecainide therapy in type 3 long QT syndrome.
    Chorin E; Taub R; Medina A; Flint N; Viskin S; Benhorin J
    Europace; 2018 Feb; 20(2):370-376. PubMed ID: 28339995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation.
    Benito B; Brugada R; Perich RM; Lizotte E; Cinca J; Mont L; Berruezo A; Tolosana JM; Freixa X; Brugada P; Brugada J
    Heart Rhythm; 2008 Oct; 5(10):1434-40. PubMed ID: 18929331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics.
    Terrenoire C; Wang K; Tung KW; Chung WK; Pass RH; Lu JT; Jean JC; Omari A; Sampson KJ; Kotton DN; Keller G; Kass RS
    J Gen Physiol; 2013 Jan; 141(1):61-72. PubMed ID: 23277474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge.
    Priori SG; Napolitano C; Schwartz PJ; Bloise R; Crotti L; Ronchetti E
    Circulation; 2000 Aug; 102(9):945-7. PubMed ID: 10961955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flecainide provocation reveals concealed brugada syndrome in a long QT syndrome family with a novel L1786Q mutation in SCN5A.
    Kanters JK; Yuan L; Hedley PL; Stoevring B; Jons C; Bloch Thomsen PE; Grunnet M; Christiansen M; Jespersen T
    Circ J; 2014; 78(5):1136-43. PubMed ID: 24599044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiarrhythmic Action of Flecainide in Polymorphic Ventricular Arrhythmias Caused by a Gain-of-Function Mutation in the Nav 1.5 Sodium Channel.
    Amarouch MY; Swan H; Leinonen J; Marjamaa A; Lahtinen AM; Kontula K; Toivonen L; Widen E; Abriel H
    Ann Noninvasive Electrocardiol; 2016 Jul; 21(4):343-51. PubMed ID: 26965448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On optimizing therapies, Orai, and ORNs.
    Adler EM
    J Gen Physiol; 2013 Feb; 141(2):149-50. PubMed ID: 23359279
    [No Abstract]   [Full Text] [Related]  

  • 12. Multifocal Ectopic Purkinje-Related Premature Contractions Syndrome in R222Q-SCN5A Gene Mutation Carriers Treated With Flecainide.
    Basile P; Napoli G; Anaclerio M; Forleo C; Guaricci AI
    JACC Clin Electrophysiol; 2022 Oct; 8(10):1334-1336. PubMed ID: 36266013
    [No Abstract]   [Full Text] [Related]  

  • 13. Functional characterization and identification of a therapeutic for a novel SCN5A-F1760C variant causing type 3 long QT syndrome refractory to all guideline-directed therapies.
    Stutzman MJ; Gao X; Kim M; Ye D; Zhou W; Tester DJ; Giudicessi JR; Shannon K; Ackerman MJ
    Heart Rhythm; 2023 May; 20(5):709-717. PubMed ID: 36731785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Congenital long QT syndrome of particularly malignant course connected with so far unknown mutation in the sodium channel SCN5A gene.
    Uziębło-Życzkowska B; Michałkiewicz D; Jackun-Podleśna A; Gielerak G; Zienciuk-Krajka A
    Cardiol J; 2013; 20(1):78-82. PubMed ID: 23558814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.
    Hu RM; Tester DJ; Li R; Sun T; Peterson BZ; Ackerman MJ; Makielski JC; Tan BH
    Channels (Austin); 2018; 12(1):176-186. PubMed ID: 29983085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome.
    Abriel H; Wehrens XH; Benhorin J; Kerem B; Kass RS
    Circulation; 2000 Aug; 102(8):921-5. PubMed ID: 10952963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment.
    Kim HJ; Kim BG; Park JE; Ki CS; Huh J; Youm JB; Kang JS; Cho H
    Sci Rep; 2019 Sep; 9(1):12997. PubMed ID: 31506521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine.
    Valdivia CR; Ackerman MJ; Tester DJ; Wada T; McCormack J; Ye B; Makielski JC
    Cardiovasc Res; 2002 Aug; 55(2):279-89. PubMed ID: 12123767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 Patients.
    Cano J; Zorio E; Mazzanti A; Arnau MÁ; Trenor B; Priori SG; Saiz J; Romero L
    Front Pharmacol; 2020; 11():580481. PubMed ID: 33519442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Channel openings are necessary but not sufficient for use-dependent block of cardiac Na(+) channels by flecainide: evidence from the analysis of disease-linked mutations.
    Liu H; Tateyama M; Clancy CE; Abriel H; Kass RS
    J Gen Physiol; 2002 Jul; 120(1):39-51. PubMed ID: 12084774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.